

Supporting Information:

Diversification of α -Ketoamides via Transamidation Reactions with Alkyl and Benzyl Amines at Room Temperature

^aDepartment of Chemistry, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh-221005;

Email: jeyakumar.chy@iitbhu.ac.in

^bDepartment of Chemistry, Pondicherry University, Pondicherry-605014

S. No.	Table of contents:	Page No.
1	Optimization Study	S2
2	General information	S3
3	General procedure for the synthesis of Amides (1d , 1e and 1n)	S3
4	General procedure for the synthesis of <i>N</i> -Boc α -ketoamides (1f-1j , 1ha-1hh)	S5
5	General procedure for the synthesis of <i>N</i> -tosyl α -ketoamides (1k , 1l and 1ka-1kk)	S8
6	Procedure for the synthesis of <i>N</i> -methyl- <i>N</i> -nitroso-2-oxo-2-phenylacetamide (1m):	S12
7	General procedure for the transamidation of <i>N</i> -tosyl amides with alkyl amines	S12
8	General procedure for the transamidation reaction of <i>N</i> -Boc amides with alkyl amines	S12
9	References	S20
10	¹ H and ¹³ C NMR Spectra of the Amides (1d , 1e and 1n) (Figures 6.1-6.3)	S21-S23
11	¹ H and ¹³ C NMR Spectra of the <i>N</i> -Boc- α -ketoamides: 1h , 1ha-1hh (Figures 6.4-6.16)	S24-S36
12	¹ H and ¹³ C NMR Spectra of the <i>N</i> -Tosyl α -ketoamides (1k , 1l , 1ka-1kk ,) (Figures 6.17-6.29)	S37-S49
13	¹ H and ¹³ C NMR spectra of <i>N</i> -nitroso <i>N</i> -methyl α -keto-amide 1m : Figures 6.30)	S50
14	¹ H and ¹³ C NMR spectra of α -ketoamides 3a-3r , 4a-4k (Figures 6.31-6.59)	S51-S79
15	HRMS of all unknown compounds	S80-S91
16	IR spectra of 1k , 3f and 3l	S92-S93

1. Optimization Study: Transamidation of N-Boc α -Ketoamide **1g** with benzylamine:

The optimization of reaction condition was investigated using *N*-Boc *N*-phenyl α -ketoamide (**1g**, 1 mmol) and benzylamine (**2a**, 1.5 mmol) as model substrates (**SI-Table 1**). Initially, the reaction was tested in different solvents (AR grade) including THF, acetonitrile, dichloromethane, toluene and DMSO in the absence of base or additives. However, the desired product **3a** was not observed even after 6 h at room temperature (Table 1, entries 1-5). Therefore, the reaction was further investigated in the presence of different organic and inorganic bases (1.0 equiv.) in dichloromethane (Table 1, entries 6-12). Among them, Cs₂CO₃ gave the desired product **3a** relatively in high yield, i.e. 68% (Table 1, entry 6). The optimization of the reaction was further continued by increasing the equivalence of Cs₂CO₃. To our delight, **3a** was achieved in 84% yield in the presence of 1.5 equiv. of Cs₂CO₃ within 2 h at room temperature (Table 1, entry 13).

SI-Table 1. Optimization of transamidation of *N*-Boc *N*-phenyl α -ketoamide (**1g**) with benzylamine (**2a**).^{a,b}

Entry	Base	Equiv.	Solvent	Time	Yield(%) ^b
1.	-	-	THF	6 h	nr
2.	-	-	CH ₃ CN	6 h	nr
3.	-	-	DCM	6 h	nr
4.	-	-	Toluene	6 h	nr
5.	-	-	DMSO	6 h	nr
6.	Cs ₂ CO ₃	1.0	DCM	6 h	68
7.	K ₂ CO ₃	1.0	DCM	6 h	20
8.	CsF	1.0	DCM	6 h	34
9.	Et ₃ N	1.0	DCM	6 h	21
10.	DBU	1.0	DCM	6 h	66
11.	DABCO	1.0	DCM	6 h	47
12.	Pyridine	1.0	DCM	6 h	nr
13.	Cs ₂ CO ₃	1.5	DCM	2 h	84
14.	Cs ₂ CO ₃	2.0	DCM	2 h	80 ^c
15.	Cs ₂ CO ₃	3.0	DCM	2 h	70 ^c
16.	Cs ₂ CO ₃	1.5	THF	2 h	70
17.	Cs ₂ CO ₃	1.5	CH ₃ CN	2 h	77

^aReaction conditions: Substrate (**1g**, 1 mmol, 325 mg), benzylamine (**2a**, 1.5 mmol, 0.164 mL) and base were stirred in solvents (AR grade) (3 mL) for an appropriate time. ^bIsolated yield. ^c5-10% of Boc-deprotected parent amide was observed.

In fact, a decrease in yield was observed with 2.0 and 3.0 equiv. of Cs_2CO_3 (Table 1, entries 14 and 15). In these cases, considerable amount ($\sim 5\text{-}10\%$) of deprotection of Boc group in **1g** was observed indicating that N-Boc amides are not stable under strong basic conditions. Moreover, the transamidation reactions in THF and acetonitrile in the presence of Cs_2CO_3 also gave the desired product **3a**, however in low yields (Table 1, entries 16 and 17).

2. EXPERIMENTAL SECTION


2.1 General information: Solvents (AR grade) and chemicals were purchased from commercial sources and used without further purifications. Aryl methyl ketones, amines and bases were obtained from Sigma-Aldrich, Alfa Aesar and Avra chemicals. The reactions were carried out in round bottom flask unless otherwise stated. Thin-layer chromatography was performed using pre-coated plates purchased from E. Merck (TLC silica gel 60 F254). TLC plates were visualized by exposure to ultraviolet light (UV) with 254 nm of wavelength and then further analyzed by using iodine chamber. The column chromatography was performed on silica gel (100-200 mesh) using a mixture of ethyl acetate/hexane as eluent. The ^1H and ^{13}C NMR spectra were recorded on *BrukerAvance 500 MHz NMR spectrometer* using CDCl_3 . HRMS-Mass spectra were recorded on UHD Q-Tof (ESI-Tof) using *water's Quattro Micro V 4.1* mass analyzer. In ^1H NMR and ^{13}C NMR spectra, CDCl_3 peak is graduated to 7.26 ppm and 77.00 ppm respectively. The ^1H NMR and ^{13}C NMR of the known products were compared with literature reports.

3.0 General procedure for the synthesis of α -Ketoamides:

i) Synthesis of amides **1a-1c**:

The α -ketoamides **1a-1c** were prepared using the literature reports.¹


ii) Synthesis of amides **1d, 1e, and 1n**:



2-Oxo-2-phenylacetic acid (1 mmol, 0.150 gm) was taken in a round bottom flask under N_2 atmosphere in DCM and cooled to $0\text{ }^\circ\text{C}$ to which thionyl chloride (2 mmol, 0.145 mL) was added. The reaction mixture was allowed to stir for 1 hour after which a mixture of amine (1.5


mmol) and triethylamine (2 mmol, 0.264 mL) was added at 0°C and stirred till the completion of reaction at room temperature. Reaction was monitored by thin layer chromatography. After that, the reaction mixture was diluted with ethyl acetate, and washed with brine and H₂O. The organic layer was dried over Na₂SO₄, filtered and evaporated under reduced pressure to give crude product, which was purified by column chromatography on silica gel to afford the title compounds **1d**, **1e**, and **1n**.

3.1 N-ethyl-2-oxo-N,2-diphenylacetamide (1d)²: The title compound was obtained as a pale



yellow solid. M.p. 92–94 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.62; Yield 76% (191 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.83 (d, J = 7.3 Hz, 2H), 7.56 (t, J = 7.4 Hz, 2H), 7.42 (t, J = 7.7 Hz, 2H), 7.23 (d, J = 6.9 Hz, 2H), 7.12 (dd, J = 7.3, 1.7 Hz, 2H), 3.97 (q, J = 7.2 Hz, 2H), 1.27 (t, J = 7.2 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 190.8, 166.6, 139.3, 134.1, 133.6, 129.4, 129.3, 128.7, 128.6, 128.3, 43.5, 12.9.


3.2N-benzyl-2-oxo-N,2-diphenylacetamide (1e)^{3a}: The title compound was obtained sticky



solid. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.60; Yield 95% (235 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.88–7.82 (m, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.33–7.28 (m, 5H), 7.17–7.11 (m, 3H), 6.95 (dd, J = 7.8, 1.5 Hz, 2H), 5.09 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 190.5, 166.9, 139.3, 136.2, 134.2, 133.5, 129.3, 129.2, 128.8, 128.7, 128.6, 128.3,

128.2, 127.8, 52.3.


3.3 1-(2-oxo-2-phenylacetyl)piperidine-2,6-dione (1n): The title compound was obtained as a



dirty white wax. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.55; Yield 80% (195 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.01–8.03 (m, 2H), 7.65 (td, J = 7.6, 1.1 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 2.75 (td, J = 6.6, 1.5 Hz, 4H), 2.06 (dt, J = 6.3, 5.1 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 183.8, 171.8,


166.5, 134.7, 131.4, 130.5, 128.7, 32.6, 16.6. HRMS: Calc. for C₁₃H₁₂NO₄ [M+H]⁺: 246.0766, Obser.: 246.0766.

iii) General procedure for the Synthesis of *N*-Boc α -ketoamides (**1f-1j**, **1ha-1hh**):




To a stirred solution of amide (1.0 mmol, 1.0 equiv.) and DMAP (0.1 equiv., 12 mg) in dichloromethane (5 mL) was added di-*tert*-butyl dicarbonate (Boc_2O) (1.3 equiv., 0.3 mL) or (2.6 equiv., 0.6 mL for **1f**) at room temperature. The resulting reaction mixture was allowed to stir for 10-12 h at room temperature. After completion, the reaction mixture was quenched with saturated solution of NaHCO_3 (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers was washed with water (1×20 mL) and brine (1×20 mL), and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO_2 : ethyl acetate/hexane) to obtain the *N*-Boc- α -keto-amides **1f-1j**, **1ha-1hh**.

3.4 *tert*-butyl (2-oxo-2-phenylacetyl)carbamate (**1f**):




The title compound was obtained as a colourless liquid. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (70:30), $R_f = 0.35$; Yield 70% (174 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.46 (s, 1H), 8.16 (s, 2H), 7.67 (d, J = 0.7 Hz, 1H), 7.52 (t, J = 7.6 Hz, 2H), 1.47 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.4, 149.3, 134.8, 132.3, 130.5, 128.8, 84.2, 27.8. HRMS: Calc. for $\text{C}_{13}\text{H}_{16}\text{NO}_4$ $[\text{M}+\text{H}]^+$: 250.1079, Obser.: 250.1079.

3.5 *tert*-butyl (2-oxo-2-phenylacetyl)(phenyl)carbamate (**1g**):




The title compound was obtained as a white solid. M.p. 116–118°C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.32$. Yield = 85% (276 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.99 (dd, J = 8.3, 1.2 Hz, 2H), 7.64 (dd, J = 11.3, 3.9 Hz, 1H), 7.55–7.45 (m, 4H), 7.43 (dd, J = 8.4, 6.3 Hz, 1H), 7.33–7.31 (m, 2H), 1.27 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ = 187.4, 169.4, 151.6, 135.7, 134.2, 132.9, 129.5, 129.3, 128.8, 128.8, 128.2, 86.1, 27.5. HRMS: Calc. for $\text{C}_{19}\text{H}_{19}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 348.1212, Obser.: 348.1229.

3.6 *tert*-butylmethyl(2-oxo-2-phenylacetyl)carbamate (**1h**)^{3b}:




The title compound was obtained as a white solid. M.p. 72–74°C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.62$. Yield = 83% (218 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.86–7.84 (m, 2H), 7.61 (t, J = 7.4 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 3.29 (s, 3H), 1.26 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ = 187.7, 169.9, 151.7, 134.1, 132.9, 129.4, 128.7, 86.0, 29.8, 27.5.


3.7 *tert*-butyl (2-oxo-2-phenylacetyl)(propyl)carbamate (1i): The title compound was obtained as a colorless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.56$. Yield = 81% (236 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.83$ (d, $J = 8.1$ Hz, 2H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.47 (t, $J = 7.8$ Hz, 2H), 3.79–3.74 (m, 2H), 1.71 (dt, $J = 8.9, 6.7$ Hz, 2H), 1.26 (s, 9H), 0.98 (t, $J = 7.5$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 187.6, 169.6, 151.7, 133.9, 132.9, 129.3, 128.6, 85.6, 44.7, 27.4, 21.5, 11.1$. **HRMS:** Calc. for $\text{C}_{14}\text{H}_{17}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 286.1055, Obser.: 286.1062.




3.8 *tert*-butyl benzyl(2-oxo-2-phenylacetyl)carbamate (1j): The title compound was obtained as a white solid. M.p. 51–52 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.35$. Yield = 86% (292 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.83$ –7.84 (m, 2H), 7.60 (d, $J = 7.3$ Hz, 1H), 7.48 (t, $J = 7.7$ Hz, 2H), 7.43 (d, $J = 7.2$ Hz, 2H), 7.37 (t, $J = 7.4$ Hz, 2H), 7.32 (d, $J = 7.2$ Hz, 1H), 4.99 (s, 2H), 1.25 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 187.5, 169.7, 151.7, 136.7, 134.0, 132.9, 129.4, 128.8, 128.6, 128.0, 127.7, 86.0, 46.4, 27.5$. **HRMS:** Calc. for $\text{C}_{14}\text{H}_{17}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 362.1368, Obser.: 362.1352.




3.9 *tert*-butyl methyl(2-oxo-2-(*p*-tolyl)acetyl)carbamate (1ha): The title compound was obtained as a colourless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.58$. Yield = 80% (222 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.74$ (d, $J = 8.2$ Hz, 2H), 7.29 (d, $J = 7.9$ Hz, 2H), 3.29 (s, 3H), 2.43 (s, 3H), 1.28 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 187.6, 170.0, 151.7, 145.2, 130.4, 129.5, 129.5, 85.9, 29.8, 27.5, 21.8$. **HRMS:** Calc. for $\text{C}_{15}\text{H}_{19}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 300.1212, Obser.: 300.1213.



3.10 *tert*-butyl(2-(4-methoxyphenyl)-2-oxoacetyl)(methyl)carbamate (1hb): The title compound was obtained as a colourless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.58$. Yield = 81% (237 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.79$ (d, $J = 8.9$ Hz, 2H), 6.95 (d, 2H), 3.86 (s, 3H), 3.27 (s, 3H), 1.26 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 186.7, 170.0, 164.2, 151.7, 131.7, 125.8, 114.0, 85.7, 55.5, 29.7, 27.5$. **HRMS:** Calc. for $\text{C}_{15}\text{H}_{19}\text{NNaO}_5$ $[\text{M}+\text{Na}]^+$: 316.1161, Obser.: 316.1161.




3.11 *tert*-butyl(2-(3-methoxyphenyl)-2-oxoacetyl)(methyl)carbamate (1hc): The title compound was obtained as a colorless sticky liquid. The residue was




purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.53$. Yield = 78% (229 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.42\text{--}7.33$ (m, 3H), 7.13–7.15 (m, 1H), 3.84 (s, 3H), 3.28 (s, 3H), 1.29 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 187.5, 169.7, 159.9, 151.7, 134.2, 129.7, 122.4, 120.8, 112.9, 85.9, 55.5, 29.7, 27.5$. **HRMS:** Calc. for $\text{C}_{15}\text{H}_{19}\text{NNaO}_5$ $[\text{M}+\text{Na}]^+$: 316.1161, Obser.: 316.1159.

3.12 *tert*-butyl(2-(3,4-dimethoxyphenyl)-2-oxoacetyl)(methyl)carbamate (1hd): The title




compound was obtained as a colourless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.56$. Yield = 76% (245 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.47$ (d, $J = 1.7$ Hz, 1H), 7.31 (dd, $J = 8.3, 1.8$ Hz, 1H), 6.88 (d, $J = 8.4$ Hz, 1H), 3.92 (d, $J = 9.5$ Hz, 6H), 3.27 (s, 3H), 1.28 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 186.8, 169.8, 154.1, 151.7, 149.3, 126.0, 125.1, 110.3, 110.2, 85.6, 56.1, 56.0, 29.8, 27.5$. **HRMS:** Calc. for $\text{C}_{14}\text{H}_{17}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 286.1055, Obser.: 286.1062.

3.13 *tert*-butyl (2-(4-fluorophenyl)-2-oxoacetyl)(methyl)carbamate (1he): The title compound




was obtained as a colourless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.55$. Yield = 79% (222 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.89\text{--}7.86$ (m, 2H), 7.17 (t, $J = 8.6$ Hz, 2H), 3.28 (s, 3H), 1.30 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 186.2, 169.6, 166.2$ (d, $J = 256.8$ Hz), 151.8, 132.0 (d, $J = 9.6$ Hz), 129.4 (d, $J = 2.9$ Hz), 116.1 (d, $J = 22.3$ Hz), 86.0, 29.8, 27.6. **HRMS:** Calc. for $\text{C}_{14}\text{H}_{16}\text{FNNaO}_4$ $[\text{M}+\text{Na}]^+$: 304.0961, Obser.: 304.0958.

3.14 *tert*-butyl (2-(4-chlorophenyl)-2-oxoacetyl)(methyl)carbamate (1hf): The title compound



was obtained as pale yellow sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.53$. Yield = 78% (232 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.79$ (d, $J = 6.7$, 2H), 7.47 (d, 2H), 3.28 (s, 3H), 1.31 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 186.5, 169.4, 151.8, 140.6, 131.3, 130.7, 129.2, 86.1, 29.9, 27.6$. **HRMS:** Calc. for $\text{C}_{14}\text{H}_{16}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 320.0666, Obser.: 320.0664.

3.15 *tert*-butyl (2-(2-chlorophenyl)-2-oxoacetyl)(methyl)carbamate (1hg): The title compound




was obtained as a pale sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), $R_f = 0.51$. Yield = 73% (217 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.13$ (dd, $J = 7.8, 1.8$ Hz, 1H), 7.54–7.51 (m, 1H), 7.45–7.41 (m, 2H), 3.27 (s, 3H), 1.36 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 185.1, 169.7, 152.1, 135.0,$

134.7, 132.5, 131.2, 131.0, 127.2, 85.7, 29.8, 27.6. **HRMS:** Calc. for $C_{14}H_{16}ClNNaO_4$ $[M+Na]^+$: 320.0666, Obser.: 320.0662.

3.16 tert-butyl (2-(4-bromophenyl)-2-oxoacetyl)(methyl)carbamate (1hh): The title compound was obtained as colorless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:05), R_f = 0.51. Yield = 75% (256 mg). **1H NMR** (500 MHz, $CDCl_3$) δ = 7.70 (d, J = 8.5 Hz, 2H), 7.63 (d, J = 8.6 Hz, 2H), 3.27 (s, 3H), 1.30 (s, 9H). **^{13}C NMR** (125 MHz, $CDCl_3$) δ = 186.6, 169.4, 151.7, 132.1, 131.7, 130.7, 129.3, 86.0, 29.8, 27.6. **HRMS:** Calc. for $C_{14}H_{17}BrNNaO_4$ $[M+Na]^+$: 364.0160, Obser.: 364.0162.


iv) General procedure for the Synthesis of *N*-tosyl α -ketoamides (1k, 1l and 1ka-1kk)⁴:




To a solution of 2-oxo-ary/alkyl acetic acid (1 mmol) in CH_2Cl_2 (2 mL) were added oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 equiv) and DMF (two drops) at 0 °C. The mixture was stirred until gas evolution stopped. Then, the reaction mixture was concentrated under reduced pressure and was used directly in the next step. To a mixture of the *N*-phenyl sulfonamide (1 mmol), DMAP (0.5 mmol%) and Et_3N (0.155 mL, 2 mmol) in CH_2Cl_2 (10 mL) was added slowly the acyl chloride made above in CH_2Cl_2 (2 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 h. Then the reaction mixture was washed with 5% HCl, brine and H_2O . The organic layer was dried over Na_2SO_4 , filtered and evaporated under reduced pressure to give crude product, which was purified by column chromatography on silica gel to afford *N*-tosyl α -ketoamides **1k**, **1l** and **1ka-1kk**.

3.17 2-oxo-*N*,2-diphenyl-*N*-tosylacetamide (1k)⁵: The title compound was obtained as a colourless oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.52; Yield 93% (351 mg). IR: 3061, 2921, 1700, 1377, 1229, 1173. **1H NMR** (500 MHz, $CDCl_3$) δ = 7.94 (d, J = 7.4 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.63–7.62 (m, 1H), 7.53 (t, J = 7.8 Hz, 2H), 7.45–7.32 (m, 5H), 7.13 (d, J = 7.3 Hz, 2H), 2.47 (s, 3H). **^{13}C NMR** (125 MHz, $CDCl_3$) δ = 187.6, 166.7, 145.9, 134.6, 134.0, 133.4, 132.7, 130.5, 130.2, 129.7, 129.6, 129.4, 129.0, 128.9, 21.8.


3.18 *N*-methyl-2-oxo-2-phenyl-*N*-tosylacetamide (1l)⁵: The title compound was obtained as yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (70:30), R_f = 0.60; Yield 78% (137 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.95–7.93 (m, 2H), 7.93–7.89 (m, 2H), 7.66–7.62 (m, 1H), 7.52 (dd, J = 10.6, 4.6 Hz, 2H), 7.39 (d, J = 6.7 Hz, 2H), 3.24 (s, 3H), 2.45 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 188.0, 167.2, 145.9, 134.4, 133.4, 132.7, 130.1, 129.6, 128.8, 128.3, 30.7, 21.7. HRMS: Calc. for C₁₆H₁₆NO₄S [M+H]⁺: 318.0800, Obser.: 318.0807.




3.19 2-oxo-*N*-phenyl-2-(*p*-tolyl)-*N*-tosylacetamide (1ka)⁵: The title compound was obtained as pale yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.48; Yield 82% (321 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.80 (dd, J = 25.8, 6.6 Hz, 4H), 7.44–7.31 (m, 8H), 7.14 (s, 2H), 2.47 (s, 3H), 2.44 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.2, 166.7, 145.9, 145.8, 134.1, 133.5, 130.5, 130.2, 130.1, 129.7, 129.7, 129.4, 129.0, 21.9, 21.7.




3.20 2-(4-methoxyphenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kb)⁵: The title compound was obtained as pale yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.52; Yield 83% (338 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.88 (d, J = 8.7 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H), 7.42–7.33 (m, 4H), 7.14 (d, J = 7.3 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H), 2.47 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 186.2, 166.9, 164.8, 145.7, 134.2, 133.6, 132.0, 130.6, 130.1, 129.7, 129.4, 129.0, 125.6, 114.3, 55.6, 21.7.



3.21 2-(3-methoxyphenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kc): The title compound was obtained as pale yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.55; Yield 81% (330 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.75 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 7.5 Hz, 1H), 7.45–7.41 (m, 3H), 7.41–7.33 (m, 4H), 7.20–7.17 (m, 1H), 7.13 (d, J = 7.3 Hz, 2H), 3.85 (s, 3H), 2.47 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.3, 166.5, 159.9, 145.8, 133.3, 130.5, 130.2, 129.9, 129.7, 129.4, 129.0, 122.7, 121.5, 112.7, 55.4, 21.7. HRMS: Calc. for C₂₂H₂₀NO₅S [M+H]⁺: 410.1062, Obser.: 410.1069.




3.22 2-(3,4-dimethoxyphenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kd): The title compound was obtained as a pale yellow sticky solid. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.54; Yield 80% (350 mg). ¹H NMR (500 MHz, CDCl₃)




δ = 7.79 (d, J = 8.1 Hz, 2H), 7.51 (dd, J = 8.3, 1.8 Hz, 1H), 7.42 (dd, J = 8.7, 6.1 Hz, 2H), 7.36 (dd, J = 14.2, 7.9 Hz, 4H), 7.13 (d, J = 7.3 Hz, 2H), 6.94 (d, J = 8.4 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 2.47 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.3, 166.6, 154.7, 149.4, 145.8, 134.2, 133.6, 130.6, 130.1, 129.7, 129.4, 129.1, 125.8, 125.8, 110.4, 110.1, 56.2, 56.0, 21.7. **HRMS**: Calc. for $\text{C}_{23}\text{H}_{22}\text{NO}_6\text{S}$ $[\text{M}+\text{H}]^+$: 440.1168, Obser.: 440.1172.

3.23 2-(4-fluorophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1ke)⁵: The title compound was




obtained as a pale yellow solid. M.p. 159–161 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.52; Yield 75% (297 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.98 (dd, J = 8.7, 5.3 Hz, 2H), 7.74 (d, J = 8.3 Hz, 2H), 7.39 (ddd, J = 24.7, 16.3, 7.8 Hz, 5H), 7.23–7.17 (m, 2H), 7.13 (d, J = 7.4 Hz, 2H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 185.9, 167.5, 166.4 (d, J = 256 Hz), 166.4, 145.9, 133.8, 133.3 (d, J = 9.8 Hz), 132.2, 130.4, 130.2, 129.7, 129.4, 129.1 (d, J = 23.2 Hz), 128.9, 116.3, 116.2, 21.7.

3.24 2-(4-chlorophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kf)⁵: The title compound was




obtained as a pale yellow solid. M.p. 157–159 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.55; Yield 78% (322 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.89 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 8.3 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.46–7.34 (m, 5H), 7.12 (d, J = 7.4 Hz, 2H), 2.47 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.3, 166.4, 146.0, 141.2, 133.8, 133.3, 131.1, 130.9, 130.4, 130.3, 129.5, 129.4, 129.0, 128.9, 21.8.

3.25 2-(2-chlorophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kg)⁵: The title compound was



obtained as a pale yellow solid. M.p. 158–151 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.50; Yield 74% (306 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.08 (s, 1H), 7.76 (d, J = 7.2 Hz, 2H), 7.52 (dt, J = 23.6, 7.7 Hz, 2H), 7.46–7.31 (m, 6H), 7.14 (d, J = 5.7 Hz, 2H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 185.4, 166.1, 145.7, 135.1, 135.0, 134.0, 133.4, 132.4, 131.2, 131.0, 130.2, 130.1, 129.6, 129.4, 129.0, 127.1, 21.7. **HRMS**: Calc. for $\text{C}_{21}\text{H}_{18}\text{NClO}_4\text{S}$ $[\text{M}+\text{H}]^+$: 414.0567, Obser.: 414.0566.


3.26 2-(4-bromophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1kh)⁵: The title compound was



obtained as pale yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.50; Yield 78% (356 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.81 (d, J = 8.4 Hz, 2H), 7.73–7.67 (m, 4H), 7.46–7.34 (m, 5H), 7.12 (d, J = 7.4


Hz, 2H), 2.47 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.5, 166.3, 146.0, 133.8, 133.3, 132.4, 131.5, 130.9, 130.4, 130.3, 130.1, 129.8, 129.5, 129.0, 21.8.

3.27 2-(4-nitrophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (1ki): The title compound was




obtained as a colorless sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.30; Yield 76% (321 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.39 (d, J = 8.8 Hz, 2H), 8.15 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.49–7.44 (m, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 7.3 Hz, 2H), 2.48 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ = 185.7, 166.0, 151.0, 146.3, 137.3, 133.4, 133.0, 130.6, 130.5, 130.3, 129.9, 129.6, 129.0, 124.1, 21.8. **HRMS:** Calc. for $\text{C}_{21}\text{H}_{17}\text{N}_2\text{O}_6\text{S}$ $[\text{M}+\text{H}]^+$: 425.0807, Obser.: 425.0805.

3.28 2-oxo-*N*-phenyl-2-(pyridin-4-yl)-*N*-tosylacetamide (1kj): The title compound was




obtained as a white solid. M.p. 114–116 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (70:30), R_f = 0.35; Yield 76% (288 mg). ^1H NMR (500 MHz, CDCl_3) δ = 9.15 (d, J = 1.5 Hz, 1H), 8.86 (dd, J = 4.8, 1.5 Hz, 1H), 8.25–8.24 (m, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.51–7.44 (m, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.37–7.33 (m, 2H), 7.12 (d, J = 7.4 Hz, 2H), 2.48 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.3, 166.0, 154.5, 150.9, 146.2, 136.6, 133.6, 133.2, 130.3, 129.8, 129.6, 129.0, 128.5, 123.8, 21.8. **HRMS:** Calc. for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{NaO}_4\text{S}$ $[\text{M}+\text{Na}]^+$: 403.0728, Obser.: 403.0728.

3.29 2-oxo-*N*-phenyl-*N*-tosylpropanamide (1kk): The title compound was obtained as



colourless oil. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.65; Yield 85% (268 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.66 (d, J = 8.4 Hz, 2H), 7.47–7.38 (m, 3H), 7.32 (d, J = 8.0 Hz, 2H), 7.07–7.05 (m, 2H), 2.52 (s, 3H), 2.45 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 194.6, 167.5, 145.9, 134.8, 133.4, 130.2, 130.1, 129.7, 129.4, 128.9, 26.8, 21.7. **HRMS:** Calc. for $\text{C}_{16}\text{H}_{16}\text{NO}_4\text{S}$ $[\text{M}+\text{H}]^+$: 318.0800, Obser.: 318.0798

v) Synthesis of *N*-methyl-*N*-nitroso-2-oxo-2-phenylacetamide (1m):




N-Methyl-2-oxo-2-phenylacetamide **1b** (163 mg, 1 mmol) was stirred in dichloromethane (3 mL) for approximately 2 min at room temperature to which tert-butyl nitrite (0.176 mL, 1.5 mmol)

was added *via* a syringe and allowed to stir for 1 h. After completion, dichloromethane was evaporated and then subjected to silica gel (60–120 mesh) column chromatography purification (SiO₂: ethyl acetate/hexane) to obtain the title compound (**1m**) obtained as yellow oil as non-separable isomers(1.0:0.5). Column chromatography was performed with hexane: EtOAc (90:10), R_f = 0.75; Yield 60% (115 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.02 (dd, *J* = 8.3, 1.0 Hz, 2H), 7.92 (dd, *J* = 8.3, 1.0 Hz, 4H), 7.71–7.64 (m, 3H), 7.56–7.49 (m, 6H), 3.98 (s, 3H), 3.28 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ = 188.5, 186.0, 172.4, 164.0, 135.3, 135.0, 132.5, 130.1, 129.5, 129.2, 128.9, 52.8, 25.5. This compound was found unstable during the mass spectrum analysis. Hence, HRMS could not be obtained.


4.0 Procedures for the transamidation reactions

i) General procedure for the transamidation of *N*-tosyl amides with alkyl amines:




To a stirred solution of alkyl amine (1.1 mmol) in DCM (3 mL) was added *N*-tosyl α -ketoamide **1k**, **1l**, **1ka-1kk** (1 mmol) at room temperature. The resulting mixture was allowed to stir for 30 min. After completion, the reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (3 $\times$ 30 mL). The combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under vacuum. The residue was purified by column chromatography on silica gel (gradient eluent of EtOAc in hexane) to give the desired products **3a-3o** and **4a-4k**.

ii) General procedure for the transamidation reaction of *N*-Boc amides with alkyl amines:




To a stirred solution of alkyl amine (1.5 mmol) and cesium carbonate (1.5 mmol, 489 mg) in DCM (3 mL) was added *N*-Boc α -ketoamide **1f-1j**, **1ha-1hh** (1 mmol) at room temperature. The resulting mixture was allowed to stir for 2 hours. After completion, the reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (3 $\times$ 30 mL). The combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under vacuum. The residue was purified by column chromatography on silica gel (gradient eluent of EtOAc in hexane) to give the desired products **3a-3o** and **4a-4h**.


4.1 N-Benzyl-2-oxo-2-phenylacetamide (3a)^{6a}: The title compound was obtained as yellow gum. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), R_f = 0.39. Yield = 96% (229 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.38–8.36 (m, 2H), 7.65–7.62 (m, 1H), 7.51–7.47 (m, 2H), 7.41 (s, 1H), 7.37–7.29 (m, 5H), 4.58 (d, J = 6.1 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.5, 161.5, 137.1, 134.5, 133.3, 131.2, 128.9, 128.5, 127.9, 127.9, 43.5. The title compound **3a** was also obtained from from **1h** 31% (74 mg); from **1i** 84% (201 mg); from **1j** in 79% (189 mg);) from **1k** in 75% (179 mg); from **1l** in 80% (191 mg); from **1m** 94% (225 mg); and from **1n** 96% (229 mg).




4.2 2-Oxo-2-phenyl-N-propylacetamide (3b)^{6a}: The title compound was obtained as colourless oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), R_f = 0.35. Yield = 95% (181 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.28–8.27 (m, 2H), 7.59–7.57 (m, 1H), 7.44–7.43 (t, J = 8.1 Hz, 2H), 7.23 (s, 1H), 3.34–3.39 (m, 2H), 1.63–1.55 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 188.0, 161.9, 134.2, 133.3, 131.0, 128.3, 41.0, 22.4, 11.2. The title compound **3b** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 93% (178 mg); from **1m** 90% (171 mg) from **1n** 91% (173 mg).




4.3 N-Butyl-2-oxo-2-phenylacetamide (3c)^{6a}: The title compound was obtained as yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), R_f = 0.48. Yield = 92% (188 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.34–8.32 (m, 2H), 7.63–7.60 (m, 1H), 7.48–7.45 (m, 2H), 7.11 (s, 1H), 3.41–3.37 (m, 2H), 1.60–1.56 (m, 2H), 1.42–1.38 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.9, 161.7, 134.3, 133.4, 131.2, 128.4, 39.1, 31.3, 20.0, 13.7. The title compound **3c** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 91% (187 mg).



4.4 2-Oxo-2-phenyl-N-propylacetamide (3d)^{6a}: The title compound was obtained as pale yellow viscous oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), R_f = 0.25. Yield = 92% (214 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.34–8.33 (m, 2H), 7.65–7.59 (m, 1H), 7.51–7.44 (m, 2H), 7.10 (s, 1H), 3.39 (dd, J = 13.4, 7.1 Hz, 2H), 1.60 (dd, J = 14.7, 7.5 Hz, 2H), 1.43–1.26 (m, 7H), 0.91–0.88 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.9, 161.7, 134.3, 133.4, 131.2, 128.4, 39.5, 31.4, 29.2, 26.5, 22.5, 14.0. The title compound **3d** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 89% (220 mg).




4.5 N-Isopropyl-2-oxo-2-phenylacetamide (3e)⁷: The title compound was obtained as a off white solid. M.p. 77–78°C. The residue was purified by column




chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.42$. Yield = 94% (179 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.34\text{--}8.32$ (m, 2H), 7.63–7.60 (m, 1H), 7.49–7.46 (m, 2H), 6.92 (s, 1H), 4.18–4.12 (m, 1H), 1.26 (d, $J = 6.6$ Hz, 6H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 188.0, 160.9, 134.3, 133.4, 131.2, 128.4, 41.7, 22.4$. The title compound **3e** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 85% (162 mg).


4.6 2-Oxo-*N*-(pentan-3-yl)-2-phenylacetamide (3f): The title compound was obtained as sticky liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.35$. Yield = 89% (194 mg). IR: 3000, 2953, 1708, 1672, 1480, 1235 $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.34\text{--}8.32$ (m, 2H), 7.62–7.59 (m, 1H), 7.49–7.45 (m, 2H), 6.83 (s, 1H), 3.89–3.82 (m, 1H), 1.69–1.61 (m, 2H), 1.53–1.44 (m, 2H), 0.94 (t, $J = 7.5$ Hz, 6H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 188.10, 161.6, 134.3, 133.4, 131.2, 128.4, 52.5, 27.3, 10.2$. HRMS: Calc. for $\text{C}_{13}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{Na}]^+$: 220.1338, Obs.: 220.1344. The title compound **3f** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 83% (181 mg); from **1m** 83% (181 mg) from **1n** 81% (177 mg).




4.7 *N*-Cyclopropyl-2-oxo-2-phenylacetamide (3g): The title compound was obtained as colorless oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.32$. Yield = 94% (177 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.32\text{--}8.31$ (m, 2H), 7.62–7.58 (m, 1H), 7.47–7.44 (m, 2H), 7.22 (s, 1H), 2.87–2.83 (m, 1H), 0.89–0.85 (m, 2H), 0.66–0.62 (m, 2H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 187.5, 163.1, 134.4, 133.2, 131.2, 128.4, 22.5, 6.4$. The title compound **3g** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 86% (163 mg).



4.8 *N*-Cyclohexyl-2-oxo-2-phenylacetamide (3h): The title compound was obtained as colourless gum. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.20$. Yield = 91% (210 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.34\text{--}8.32$ (m, 2H), 7.63–7.60 (m, 1H), 7.49–7.46 (dd, $J = 11.1, 4.6$ Hz, 2H), 6.95 (s, 1H), 3.89–3.83 (m, 1H), 2.0–1.97 (m, 2H), 1.78–1.75 (m, 2H), 1.65–1.64 (m, 1H), 1.44–1.38 (m, 2H), 1.32–1.21 (m, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 188.1, 160.8, 134.3, 133.5, 131.2, 128.4, 48.5, 32.7, 25.4, 24.7$. The title compound **3h** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 87% (201 mg).




4.9 *N*-(4-fluorobenzyl)-2-oxo-2-phenylacetamide (3i): The title compound was obtained as white solid. M.p. 84–86 °C The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.39$. Yield = 93% (238 mg). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.3\text{--}$




8.28 (m, 2H), 7.6–7.60 (m, 1H), 7.53–7.43 (m, 3H), 7.33–7.27 (m, 2H), 7.02 (td, $J = 8.7, 2.8$ Hz, 2H), 4.53 (d, $J = 6.1$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 187.4, 163.2, 161.5, 161.3, 134.4, 133.2, 132.9, 131.1, 129.6, 129.5, 128.4, 115.7, 115.5, 42.7$. The title compound **3i** was also obtained from **1g** 91% (233 mg).


4.10 N-(4-methoxybenzyl)-2-oxo-2-phenylacetamide(3j)^{6c}: The title compound was obtained as yellow solid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:10), $R_f = 0.39$. Yield = 95% (255 mg). ^1H NMR (500 MHz, CDCl_3) $\delta = 8.36$ (dd, $J = 8.3, 1.2$ Hz, 2H), 7.67–7.61 (m, 1H), 7.50 (dd, $J = 11.0, 4.7$ Hz, 2H), 7.43 (s, 1H), 7.28 (d, $J = 7.9$ Hz, 2H), 6.95–6.85 (m, 2H), 4.52 (d, $J = 6.0$ Hz, 2H), 3.81 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 187.6, 161.5, 159.1, 134.3, 133.2, 131.1, 129.2, 129.1, 128.4, 114.1, 55.2, 42.9$. The title compound **3j** was also obtained **1g** 94% (252 mg).




4.11 2-Oxo-2-phenyl-N-(pyridin-2-ylmethyl)acetamide (3k)⁹: The title compound was obtained as orange viscous liquid. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (90:20), $R_f = 0.21$. Yield = 95% (227 mg). ^1H NMR (500 MHz, CDCl_3) $\delta = 8.60$ (d, $J = 4.4$ Hz, 1H), 8.36 (d, $J = 7.6$ Hz, 2H), 8.21 (s, 1H), 7.72–7.62 (m, 2H), 7.51 (t, $J = 7.8$ Hz, 2H), 7.32 (s, 1H), 7.24 (dd, $J = 7.1, 5.3$ Hz, 1H), 4.72 (d, $J = 5.4$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 187.6, 162.0, 155.5, 149.3, 136.9, 134.3, 133.3, 131.1, 128.5, 122.6, 122.0, 44.3$. The title compound **3k** was also obtained from *N*-Boc*N*-phenyl α -ketoamide **1g** in 90% (216 mg).




4.12 2-Oxo-2-phenyl-N-(2-(pyridin-2-yl)ethyl)acetamide (3l): The title compound was obtained as a white solid. M.p. 46–48 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (95:20), $R_f = 0.15$; Yield = 93% (236 mg). IR: 2966, 2871, 1710, 1677, 1544, 1287. ^1H NMR (500 MHz, CDCl_3) $\delta = 8.56$ (d, $J = 4.7$ Hz, 1H), 8.30–8.28 (m, 2H), 7.92 (s, 1H), 7.64–7.58 (m, 2H), 7.47–7.44 (m, 2H), 7.19–7.15 (m, 2H), 3.84–3.81 (m, 2H), 3.09 (t, $J = 6.4$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) $\delta = 187.9, 162.0, 158.9, 149.3, 136.7, 134.2, 133.4, 131.1, 128.4, 123.4, 121.7, 38.5, 36.6$. HRMS: Calc. for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_2$ $[\text{M}+\text{Na}]^+$: 255.1134, Obser.: 255.1147. The title compound **3l** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 89% (226 mg); from **1m** 90% (227 mg) from **1n** 91% (229 mg).




4.13 *N,N*-Diethyl-2-oxo-2-phenylacetamide (3m)^{6a}: The title compound was obtained as a colorless oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), $R_f = 0.25$. Yield = 85% (174 mg). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.91$ (d, $J = 8.4$ Hz, 2H), 7.61 (t, $J = 7.4$




Hz, 1H), 7.48 (t, J = 7.8 Hz, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.22 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H), 1.13 (t, J = 7.1 Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 191.5, 166.6, 134.4, 133.1, 129.5, 128.8, 77.2, 77.0, 76.7, 42.0, 38.7, 14.0, 12.7. The title compound **3m** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 73% (150 mg); from **1m** 82% (170 mg) from **1n** 88% (180 mg).




4.14 2-Phenyl-1-(pyrrolidin-1-yl)ethan-1-one (3n)⁷: The title compound was obtained as yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.26. Yield = 88% (168 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.02–7.98 (m, 2H), 7.65–7.62 (m, 1H), 7.52–7.49 (m, 2H), 3.66 (t, J = 6.8 Hz, 2H), 3.43 (t, J = 6.4 Hz, 2H), 1.95–1.94 (m, 4H). ^{13}C NMR (125 MHz, CDCl_3) δ = 191.6, 164.9, 134.6, 132.9, 129.9, 128.9, 46.7, 45.2, 25.9, 24.0. The title compound **3n** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 89% (181 mg).



4.15 1-Phenyl-2-(piperidin-1-yl)ethane-1,2-dione (3o)^{6a}: The title compound was obtained as a white solid. M.p. 94–95 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.20. Yield = 89% (193 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.98 – 7.92 (m, 2H), 7.67 – 7.61 (m, 1H), 7.51 (t, J = 7.7 Hz, 2H), 3.70 (s, 2H), 3.30–3.27 (m, 2H), 1.71–1.68 (m, 4H), 1.55 (d, J = 5.0 Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ = 191.9, 165.4, 134.6, 133.2, 129.6, 129.0, 47.0, 42.1, 26.2, 25.4, 24.4. The title compound **3o** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 88% (191 mg).




4.16 1-Morpholino-2-phenylethane-1,2-dione (3p)^{6a}: The title compound was obtained as yellow oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.21. Yield = 94% (205 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.97–7.95 (m, 2H), 7.67–7.64 (m, 1H), 7.54–7.51 (t, J = 7.8 Hz, 2H), 3.82–3.77 (m, 4H), 3.66–3.64 (m, 2H), 3.39–3.37 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ = 191.1, 165.4, 134.9, 133.0, 129.7, 129.1, 66.7, 66.7, 46.3, 41.6. The title compound **3p** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 85% (186 mg); from **1m** 85% (186 mg) from **1n** 89% (196 mg).




4.17 1-Morpholino-2-phenylethane-1,2-dione (3q)^{6b}: The title compound was obtained as yellow solid. M.p. 82–84 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.45. Yield = 95% (223 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.92 (d, J = 8.1 Hz, 2H), 7.64 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 4.04–3.98 (m, 2H), 3.62–3.57 (m, 2H), 2.76–2.71 (m, 2H), 2.63–2.58 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ = 191.2, 165.6, 134.8, 132.9, 129.5, 129.0, 48.6, 43.6, 27.7, 27.2. The title compound **3q** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 85% (200 mg).


4.18 1-(4-Benzhydrylpiperazin-1-yl)-2-phenylethane-1,2-dione (3r)¹⁰: The title compound was obtained as brown viscous oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.10. Yield = 89% (341 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.96–7.91 (m, 2H), 7.62 (d, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.41–7.39 (d, J = 7.3 Hz, 4H), 7.28 (d, J = 7.4 Hz, 3H), 7.21–7.17 (m, 2H), 4.28 (s, 1H), 3.80–3.78 (m, 2H), 3.38–3.36 (m, 2H), 2.54–2.52 (m, 2H), 2.37–2.36 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 191.5, 165.3, 141.8, 134.7, 133.1, 129.6, 129.0, 128.7, 127.8, 127.3, 75.8, 51.9, 51.4, 46.1, 41.4. The title compound **3r** was also obtained from *N*-Boc *N*-phenyl α -ketoamide **1g** in 84% (323 mg).




4.16 *N*-benzyl-2-oxo-2-(*p*-tolyl)acetamide (4a)⁸: The title compound was obtained as a white solid. M.p. 81.1–81.5 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.62. Yield = 92% (232 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.29 (d, J = 8.2 Hz, 2H), 7.44 (s, 1H), 7.36–7.30 (m, 5H), 7.28 (d, J = 8.0 Hz, 2H), 4.57 (d, J = 6.1 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.0, 161.8, 145.7, 137.2, 131.4, 130.8, 129.2, 128.8, 127.9, 127.8, 43.4, 21.9. The title compound **4a** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1ja** in 89% (225 mg).




4.17 *N*-benzyl-2-(4-methoxyphenyl)-2-oxoacetamide (4b)⁸: The title compound was obtained as a white solid. M.p. 95.3–95.7 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.65. Yield = 94% (22 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.44–8.42 (m, 2H), 7.51 (s, 1H), 7.37–7.29 (m, 5H), 6.96–6.93 (m, 2H), 4.56 (d, J = 6.1 Hz, 2H), 3.88 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 185.5, 164.7, 162.1, 137.2, 133.9, 128.8, 127.8, 127.7, 126.3, 113.8, 55.5, 43.4. The title compound **4b** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jbin** in 90% (242 mg).



4.18 *N*-benzyl-2-(3-methoxyphenyl)-2-oxoacetamide (4c)⁸: The title compound was obtained as colourless oil. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.55. Yield = 91% (235 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.00 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 1.3 Hz, 1H), 7.47 (s, 1H), 7.40–7.30 (m, 5H), 7.19–7.16 (m, 1H), 4.56 (d, J = 6.1 Hz, 2H), 3.85 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 187.3, 161.6, 159.5, 137.1, 134.4, 129.5, 128.9, 127.8, 127.7, 124.1, 121.4, 114.6, 55.4, 43.4. The title compound **4c** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jc** in 87% (234 mg).




4.19 *N*-benzyl-2-(3,4-dimethoxyphenyl)-2-oxoacetamide (4d)¹¹: The title compound was




obtained as a white solid. M.p. 119–121 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.59. Yield = 92% (275 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.26 (d, J = 3.6 Hz, 1H), 7.88 (dd, J = 4.5, 2.3 Hz, 1H), 7.51 (s, 1H), 7.33–7.28 (m, 5H), 6.92 (dd, J = 9.6, 6.5 Hz, 1H), 4.55 (s, 2H), 3.95 (s, 3H), 3.92 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ = 185.3, 162.1, 154.7, 148.8, 137.2, 128.8, 127.8, 127.7, 127.4, 126.4, 112.6, 110.2, 56.1, 55.9, 43.4. The title compound **4d** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jd** in 87% (260 mg).

4.20 *N*-benzyl-2-(4-fluorophenyl)-2-oxoacetamide (4e)⁸: The title compound was obtained as a



white solid. M.p. 66–67 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.60. Yield = 93% (239 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.48–8.46 (m, 2H), 7.47 (s, 1H), 7.38–7.30 (m, 5H), 7.17–7.13 (dd, J = 12.8, 4.5 Hz, 2H), 4.56 (d, J = 6.1 Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ = 185.6, 166.6 (d, J = 256.25 Hz), 161.3, 137.0, 134.3 (d, J = 10.0 Hz), 129.8 (d, J = 2.5 Hz), 128.8, 127.8, 115.8, 115.6, 43.5. The title compound **4e** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1je** in 82% (211mg).


4.21 *N*-benzyl-2-(4-chlorophenyl)-2-oxoacetamide (4f)⁸: The title compound was obtained as a



white solid. M.p. 111.9–112.3 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.63. Yield = 94% (256 mg). ^1H NMR (500 MHz, CDCl_3) δ = 8.36 (d, J = 8.6 Hz, 2H), 7.47–7.45 (m, 2H), 7.38–7.31 (m, 5H), 4.57 (d, J = 6.1 Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ = 186.1, 161.1, 141.3, 136.9, 132.7, 131.7, 129.0, 128.9, 127.90,


127.9, 43.5. The title compound **4f** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jf** in 83% (227 mg).

4.22 *N*-benzyl-2-(2-chlorophenyl)-2-oxoacetamide (4g)¹²: The title compound was obtained as




a white solid. M.p. 91–92 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.63. Yield = 81% (221 mg). ^1H NMR (500 MHz, CDCl_3) δ = 7.71–7.69 (m, 2H), 7.50–7.44 (m, 4H), 7.40–7.32 (m, 2H), 7.29 (s, 1H), 4.58 (d, J = 6.1 Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3) δ = 190.0, 160.6, 136.9, 134.0, 133.1, 131.3, 130.4, 128.9, 128.0, 127.9, 126.6, 43.7. The title compound **4g** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jg** in 72% (197 mg).

4.23 *N*-benzyl-2-(4-bromophenyl)-2-oxoacetamide (4h)⁸: The title compound was obtained as




a white solid. M.p. 113–114 °C. The residue was purified by column chromatography in silica gel eluting with hexane/EtOAc (80:20), R_f = 0.58. Yield = 95% (301 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.27 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.6 Hz, 2H), 7.43 (s, 1H), 7.37–7.32 (m, 5H), 4.56 (d, J = 6.1 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 186.3, 161.1, 136.9, 132.8, 132.1, 131.98, 130.2, 128.9, 127.9, 129.9, 43.5. The title compound **4h** was also obtained from *N*-Boc *N*-methyl α -ketoamide **1jh** in 85% (270 mg).

4.24 *N*-benzyl-2-(4-nitrophenyl)-2-oxoacetamide(4i): The title compound was obtained as a




pale yellow solid. M.p. 91–92 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.38. Yield 86% (244 mg). ¹H NMR (500 MHz, CDCl₃) δ = 8.55 (d, J = 8.8 Hz, 2H), 8.31 (d, J = 8.8 Hz, 2H), 7.47 (s, 1H), 7.39–7.35 (m, 5H), 4.59 (d, J = 6.1 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 185.9, 160.3, 150.8, 137.9, 136.6, 132.4, 128.9, 128.1, 127.9, 123.5, 43.7. HRMS: Calc. for C₁₅H₁₃N₂O₄ [M+H]⁺: 285.0875, Obser.: 285.0875.

4.25 *N*-benzyl-2-oxo-2-(pyridin-3-yl)acetamide(4j): The title compound was obtained as a



white solid. M.p. 120 °C. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.25. Yield = 91% (218 mg). ¹H NMR (500 MHz, CDCl₃) δ = 9.53 (d, J = 1.6 Hz, 1H), 8.82 (dd, J = 4.8, 1.5 Hz, 1H), 8.68 (dt, J = 8.0, 1.8 Hz, 1H), 7.54 (s, 1H), 7.44–7.42 (m, 1H), 7.38–7.30 (m, 5H), 4.57 (d, J = 6.1 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 186.4, 160.5, 154.3, 152.2, 138.6, 136.8, 129.1, 128.9, 128.0, 127.9, 123.3, 43.6. HRMS: Calc. for C₁₄H₁₂N₂NaO₂ [M+Na]⁺: 263.0796, Obser.: 263.0792.

4.26 *N*-benzyl-2-oxopropanamide (4k)¹³: The title compound was obtained as a colourless



liquid. The residue was purified by column chromatography in silica gel eluting with hexane: EtOAc (80:20), R_f = 0.30. Yield = 95% (168 mg). ¹H NMR (500 MHz, CDCl₃) δ = 7.36–7.28 (m, 5H), 7.27 (s, 1H), 4.47 (d, J = 6.1 Hz, 2H), 2.50 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 197.0, 159.9, 136.9, 128.8, 127.9, 43.5, 24.5. HRMS: Calc. for C₁₀H₁₂NO₂ [M+H]⁺: 178.0868, Obser.: 178.0861.

5. References:

1. D. Wang, K. Zhang, L. H. Jia, D. T. Zhang, Y. Zhang, Y. J. Cheng, C. Lin, B. Wang, *Org. Biomol. Chem.* **2017**, *15*, 3427-3434.
2. P. Das, H. M. Begam, S. K. Bhunia, R. Jana, *Adv. Synth. Catal.* **2019**, *361*, 4048-4054.
3. (a) C. Zhang, Z. Xu, L. Zhang, N. Jiao, *Angewandte Chemie.* **2011**, *123*, 11284-11288. (b) Sureshbabu, P., Azeez, S., Muniyappan, N., Sabiah, S., & Kandasamy, J. *The Journal of organic chemistry*, **2019**, *84*, 11823-11838.
4. X. Li, G. Zou, *Chem. Commun.*, **2015**, *51*, 5089-5092
5. X. Liu, Z. X. Zhang, B. Zhou, Z. S. Wang, R. H. Zheng, L.W. Ye, *Org. Biomol. Chem.*, **2017**, *15*, 10156-10159
6. (a) Z. L. Zhang, J. H. Su, Z. G. Zha, Z. Y. Wang, *Chem. Commun.* **2013**, *49*, 8982-8984. (b) P. H. Li, Z. Wang, H. Fu, Q. P. Dai, C. W. Hua, *Chem. Commun.*, **2018**, *54*, 12471-12474. (c) H. Cha, J. Y. Chai, H. B. Kim, D. Y. Chi, *Org. Biomol. Chem.*, **2021**, *19*, 4320-4326.
7. W. Wei, Y. Shao, H. Y. Hu, F. Zhang, C. Zhang, Y. Xu, X. B. Wan, *J. Org. Chem.* **2012**, *77*, 7157-7165.
8. Y. K. Zhang, B. Wang, *Eur. J. Org. Chem.* **2019**, *2019*, 5732-5735.
9. M. Gergely, R. Farkas, A. Takacs, A. Petz, L. Kollar, *Tetrahedron* **2014**, *70*, 218-224.
10. M. Ramanathan, C. K. Kuo, S. T. Liu, *Org. Biomol. Chem.* **2016**, *14*, 11446-11453.
11. L. Liu, L. Du, D. Zhang-Negrerie, Y. F. Du, K. Zhao, *Org. Lett.* **2014**, *16*, 5772-5775.
12. G. X. Gu, T. L. Yang, O. R. Yu, H. Qan, J. Wang, J. L. Wen, L. Dang, X. M. Zhang, *Org. Lett.* **2017**, *19*, 5920-5923.
13. Ghosh, D., Nandi, R., Khamarui, S., Ghosh, S. Maiti, D.K. *Chemical Commun.*, **2019**, *55*, 3883-3886.

6. ^1H and ^{13}C NMR Spectra of the α -ketoamides




Figure 6.1 ^1H and ^{13}C of product 1d in CDCl_3 .





Figure 6.2 ¹H and ¹³C of product 1e in CDCl₃.





Figure 6.3 ¹H and ¹³C of product 1n in CDCl₃.




Figure 6.4 ^1H and ^{13}C of product 1h in CDCl_3 .




Figure 6.5 ¹H and ¹³C NMR of product **1i** in CDCl₃.




Figure 6.6 ¹H and ¹³C NMR of product **1h** in CDCl₃.





Figure 6.7 ¹H and ¹³C NMR of product 1i in CDCl₃.




Figure 6.8 ¹H and ¹³C NMR of product 1j in CDCl₃.




Figure 6.9 ^1H and ^{13}C NMR of product 1ha in CDCl₃.




Figure 6.10 ¹H and ¹³C NMR of product 1hb in CDCl₃.




Figure 6.11 ^1H and ^{13}C NMR of product 1hc in CDCl₃.




Figure 6.12 ^1H and ^{13}C NMR of product 1hd in CDCl₃.





Figure 6.13 ¹H and ¹³C NMR of product 1he in CDCl₃.




Figure 6.14 ¹H and ¹³C NMR of product 1hf in CDCl₃.



Figure 6.15 ¹H and ¹³C NMR of product 1hg in CDCl₃.




Figure 6.16 ¹H and ¹³C NMR of product 1hh in CDCl₃.





Figure 6.17 ¹H and ¹³C of product 1k in CDCl₃.





Figure 6.18 ¹H and ¹³C of product 1l in CDCl₃.




Figure 6.19 ¹H and ¹³C of product 1ka in CDCl₃.





Figure 6.20 ¹H and ¹³C of product 1kb in CDCl₃.





Figure 6.21 ¹H and ¹³C of product 1kc in CDCl₃.




Figure 6.22 ¹H and ¹³C of product 1kd in CDCl₃.




Figure 6.23 ¹H and ¹³C of product 1ke in CDCl₃.





Figure 6.24 ¹H and ¹³C of product 1kf in CDCl₃.





Figure 6.25 ¹H and ¹³C of product 1kg in CDCl₃.





Figure 6.26 ¹H and ¹³C of product 1kh in CDCl₃.




Figure 6.27 ¹H and ¹³C of product 1ki in CDCl₃.





Figure 6.28 ¹H and ¹³C of product 1kj in CDCl₃.





Figure 6.29 ¹H and ¹³C of product 1kk in CDCl₃.





Figure 6.30 ¹H and ¹³C of product 1m in CDCl₃.

^1H and ^{13}C NMR spectra of α -keto-amides:




Figure 6.31 ^1H and ^{13}C NMR of product 3a in CDCl_3 .




Figure 6.32 ¹H and ¹³C NMR of product **3b** in CDCl₃.





Figure 6.33 ¹H and ¹³C NMR of product 3c in CDCl₃.




Figure 6.34 ¹H and ¹³C NMR of product 3d in CDCl₃.




Figure 6.35 ¹H and ¹³C NMR of product 3e in CDCl₃.




Figure 6.36 ¹H and ¹³C NMR of product **3f** in CDCl₃.




Figure 6.37 ¹H and ¹³C NMR of product **3g** in CDCl₃.



Figure 6.38 ^1H and ^{13}C NMR of product 3h in CDCl_3 .





Figure 6.39 ^1H and ^{13}C NMR of product **3i** in CDCl₃.




Figure 6.40 ¹H and ¹³C NMR of product **3j** in CDCl₃.





Figure 6.41 ¹H and ¹³C NMR of product 3k in CDCl₃.




Figure 6.42 ¹H and ¹³C NMR of product 3l in CDCl₃.





Figure 6.43 ¹H and ¹³C NMR of product 3m in CDCl₃.




Figure 6.44 ¹H and ¹³C NMR of product **3n** in CDCl₃.





Figure 6.45 ¹H and ¹³C NMR of product 3o in CDCl₃.




Figure 6.46 ¹H and ¹³C NMR of product **3p** in CDCl₃.




Figure 6.47 ¹H and ¹³C NMR of product 3q in CDCl₃.




Figure 6.48 ¹H and ¹³C NMR of product 3r in CDCl₃.




Figure 6.49 ^1H and ^{13}C NMR of product 4a in CDCl₃.




Figure 6.50 ¹H and ¹³C NMR of product 4b in CDCl₃.





Figure 6.51 ¹H and ¹³C NMR of product 4c in CDCl₃.





Figure 6.52 ¹H and ¹³C NMR of product 4d in CDCl₃.




Figure 6.53 ^1H and ^{13}C NMR of product **4e** in CDCl_3




Figure 6.54 ^1H and ^{13}C NMR of product 4f in CDCl_3 .





Figure 6.55 ¹H and ¹³C NMR of product 4g in CDCl₃.




Figure 6.56 ^1H and ^{13}C NMR of product 4h in CDCl₃.





Figure 6.57 ¹H and ¹³C of product 4i in CDCl₃.




Figure 6.58 ¹H and ¹³C of product 4j in CDCl₃.





Figure 6.59 ¹H and ¹³C of product 4k in CDCl₃.

HRMS SPECTRA:




Figure 6.60 HRMS of compound (1f):




Figure 6.61 HRMS of compound (1g):




Figure 6.62 HRMS of compound (1ha):




Figure 6.63 HRMS of compound (1hb):




Figure 6.64 HRMS of compound (1hc):




Figure 6.65 HRMS of compound (1hd):




Figure 6.66 HRMS of compound (1he):




Figure 6.67 HRMS of compound (1hf):

Sample Name	NM-2-Cl-BOC	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	NM-2-Cl-BOC.d	ACQ Method	Pondicherry Universi	Comment	NM-SS-297.08	Acquired Time	10-09-2019 11:26:36




Figure 6.68 HRMS of compound (1hg):

Sample Name	NM-4Br-BOC	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	NM-4Br-BOC.d	ACQ Method	Pondicherry Universi	Comment	NM-SS-341.03	Acquired Time	10-09-2019 11:48:28




Figure 6.69 HRMS of compound (1hh):




Figure 6.70 HRMS of compound (1i):




Figure 6.71 HRMS of compound (1j):




Figure 6.72 HRMS of compound (1kc):




Figure 6.73 HRMS of compound (1kd):

Sample Name	XY-S-13	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S-13.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-414.0561	Acquired Time	3/22/2021 11:44:15 AM




Figure 6.74 HRMS of compound (1kg):

Sample Name	XY-S-14	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S-14.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-425.0802	Acquired Time	3/22/2021 11:48:32 AM




Figure 6.75 HRMS of compound (1ki):

Sample Name	XY-S8	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S8.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-381.0925	Acquired Time	3/19/2021 1:37:56 PM




Figure 6.76 HRMS of compound (1kj):

Sample Name	XY-S4	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S4.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-318.0795	Acquired Time	3/18/2021 3:11:04 PM




Figure 6.77 HRMS of compound (1kk):

Sample Name	XY-S2	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S2.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-246.0761	Acquired Time	3/18/2021 3:00:54 PM




Figure 6.78 HRMS of compound (1n):

Sample Name	NM-Aminopentane-pot	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	NM-Aminopentane-pot.	ACQ Method	Pondicherry Universi	Comment	NM-SS-219.13	Acquired Time	12-09-2019 12:16:05




Figure 6.79 HRMS of compound (3f):




Figure 6.80 HRMS of compound (3i):




Figure 6.81 HRMS of compound (4i):

Sample Name	XY-S9	Position		Instrument Name	Q-TOF	User Name	QTOF-PU\admin
Inj Vol	-1	InjPosition		SampleType	Sample	IRM Calibration Status	Success
Data Filename	XY-S9.d	ACQ Method	Pondicherry Universi	Comment	QJ-SS-241.0972	Acquired Time	3/19/2021 1:42:17 PM




Figure 6.82 HRMS of compound **(4j)**:

IR SPECTRA:




Figure 6.85 IR spectrum of (1k)




Figure 6.86 IR spectrum of (3f)




Figure 6.87 IR spectrum of (3I)